An Update on Self-Amplifying mRNA Vaccine Development


Authors: A.K. Blakney, S. Ip. and A.J. Geall

Journal: Vaccines

DOI: 10.3390/vaccines9020097

Publication - Abstract

January 28, 2021

Vaccines Nucleic Acid Lipid Nanoparticles mRNA

Abstract

This review will explore the four major pillars required for design and development of an saRNA vaccine: Antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)). We report on the major innovations, preclinical and clinical data reported in the last five years and will discuss future prospects.
 

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Feb 04, 2020
npj Vaccines

The Promise of mRNA Vaccines: A Biotech and Industrial Perspective

N.A.C Jackson, K.E. Kester, D. Casimiro, S. Gurunathan and F. DeRosa

Vaccines Nucleic Acid Lipid Nanoparticles mRNA
mRNA technologies have the potential to transform areas of medicine, including the prophylaxis of infectious diseases. The advantages for vaccines range from the acceleration of immunogen discovery to rapid response and multiple disease target manufacturing. A greater understandi...
Read More


Publication - Abstract

Aug 03, 2020
Vaccines

Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses

S. Shirai, A. Kawai, M. Shibuya, L. Munakata, D. Omata, R. Suzuki and Y. Yoshioka

Other Payloads Vaccines Nucleic Acid Lipid Nanoparticles

In this in vitro and in vitro study, the Yoshioka lab at Osaka University investigated cytosine–phosphate–guanine oligodeoxynucleotides (CpG ODN) lipid nanoparticles (LNPs) as an adjuvant for seasonal split vaccines (SV) from influenza virus antig...

Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up